PharmaPoint, Global Drug: Colorectal Cancer Market Forecast to 2023

1
PharmaPoint Colorectal Cancer - Global Drug
Forecast and Market Analysis to
2023 www.bigmarketresearch.com
2
Report Description
Summary Colorectal cancer (CRC) is the second
leading cause of mortality among cancer patients
in the world and is the third most diagnosed
cancer globally, and thus represents a huge
burden on healthcare systems. This report focuses
on the current treatment landscape, unmet needs,
current pipeline, and commercial opportunities in
the colorectal cancer market, with coverage of
multiple settings of the disease including
neoadjuvant/adjuvant, first-, second-, third-line
KRAS wild-type and mutation-positive, and
fourth-line metastatic. In terms of targeted
treatments, the metastatic CRC treatment
landscape is mature, including the branded
treatments Avastin (bevacizumab), Erbitux
(cetuximab), and Vectibix (panitumumab),
treatments that have extended the survival of
metastatic patients compared to chemotherapy-only
regimens. Browse complete report TOC _at_
http//www.bigmarketresearch.com/pharmapoint-colo
rectal-cancer-global-drug-forecast-and-analysis-to
-2023-market
3
Report Description
However, high unmet needs remain for the
extension of survival of metastatic patients, and
particularly those with KRAS mutation-positive
disease, for whom the epidermal growth factor
receptor (EGFR) inhibitors Erbitux and Vectibix
are not recommended. The CRC market is expected
to grow due to the incorporation of five
late-stage pipeline agents during the forecast
period, including Mologens MGN1703, Eli Lillys
Cyramza, and Boehringer Ingelheims nintedanib.
Furthermore, GlobalData expects the label
extension of Stivarga as a first-line adjuvant
treatment for metastatic CRC patients with
resected liver metastases. Ultimately, however,
GlobalData expects unmet needs to remain
unfulfilled by these pipeline agents, and
anticipates that novel, innovative approaches,
such as those targeting BRAF mutation-positive
disease and immune checkpoint inhibitors, will
provide the best opportunity for substantial
improvement in the prognosis of advanced CRC
patients. Feel free to enquire about this report
_at_ http//www.bigmarketresearch.com/report-enquiry
/183885
4
Report Description

• Key Questions Answered
• What are the corporate strategies being used by
  drug makers?
• How is the disease management evolving.What is
  the impact for drug manufacturers?
• What opportunities remain after the launch of
  pipeline agents?
• How large are the metastatic KRAS wild-type and
  mutation-positive CRC markets for branded agents,
  and which are growing the fastest?
• What exciting, innovative approaches are being
  investigated in CRC.Which immunotherapies are of
  interest to the CRC market?
• What do KOLs think about the latest therapies and
  drug development strategies?

5
Report Description

• Key Findings
• By 2023, the end of the forecast period,
  GlobalData projects CRC sales to rise to 8.11
  billion in the 8MM, at a moderate Compound Annual
  Growth Rate (CAGR) of 4.9. Major drivers of the
  growth of the CRC market over the forecast period
  include increasing CRC incident cases, the launch
  of premium-priced adjuvant and maintenance
  treatments for first-line metastatic disease, and
  the launch of pipeline agents for later-line CRC.
• Roches anti-angiogenesis drug Avastin has been
  the best-selling brand in CRC for many years,
  and, after label extension in the second-line
  continuation setting, is set to remain the market
  leader across the forecast period. However,
  competition in this drug class is expected to
  become more intense, especially in the
  second-line metastatic setting, as
  Sanofi/Regenerons Zaltrap and Eli Lillys
  pipeline agent Cyramza (ramucirumab) garner
  uptake across the major markets.

6
Report Description

• Key Findings
• GlobalData expects the next surge of
  anti-angiogenesis drugs to be focused on the
  anti-Ang2 inhibitor class. This class is likely
  to be led by Roches dual anti-VEGF/Ang2
  inhibiting antibody vanucizumab (RO5520985
  RG7221). Roche is currently investigating
  vanucizumab head-to-head against Avastin in a
  randomized Phase II study. If this agent is
  successful in a large, pivotal study, GlobalData
  anticipates vanucizumab to become a key part of
  Roches strategy to overcome biosimilar erosion
  of Avastin towards the end of the forecast
  period.
• Need Discount? Request here _at_
• http//www.bigmarketresearch.com/purchase-enquiry/
  183885

7
Table of Contents
4.3 Global Trends 4.3.1 8MM, Incidence
Trends 4.3.2 8MM, Five-Year Relative
Survival 4.3.3 8MM, Screening Programs for
CRC 4.4 Forecast Methodology 4.4.1 Sources Used
4.4.2 Sources Not Used 4.4.3 Forecast
Assumptions and Methods 4.5 Epidemiological
Forecast of CRC (2013-2023) 4.5.1 Diagnosed
Incident Cases of CRC 4.5.2 Age-Specific
Diagnosed Incident Cases of CRC 4.5.3
Sex-Specific Diagnosed Incident Cases of
CRC 4.5.4 Age-Standardized Incidence 4.5.5 Cancer
Stage at Diagnosis 4.5.6 Diagnosed Five-Year
Prevalent Cases of CRC 4.5.7 KRAS Status among
Diagnosed Five-Year Prevalent Cases of CRC 4.6
Discussion
8
Table of Contents
5 Disease Management 5.1 Diagnosis and Treatment
Overview 5.1.1 Screening and Diagnosis 5.1.2
Treatment Guidelines and Leading Prescribed
Drugs 5.1.3 Clinical Practice 5.2 US 5.2.1
Screening and Diagnosis 5.2.2 Clinical
Practice 5.3 France 5.3.1 Screening and
Diagnosis 5.3.2 Clinical Practice 5.4
Germany 5.4.1 Screening and Diagnosis
9
Report Description

• Scope
• Overview of colorectal cancer, including
  epidemiology, etiology, pathophysiology,
  symptoms, diagnosis, and disease management.
• Annualized Colorectal cancer therapeutics market
  revenue, annual cost of therapy, and treatment
  usage patterns in eight patient segments,
  forecast from 2013 to 2023.
• Key topics covered include strategic competitor
  assessment, market characterization, unmet needs,
  remaining commercial opportunities, and current
  and future players for the colorectal cancer
  therapeutics market.

10
Report Description

• Scope
• Pipeline analysis comprehensive data assessing
  emerging trends and mechanisms of action under
  development for different lines of therapy. The
  most promising candidates in Phase III
  development are profiled.
• Analysis of the current and future market
  competition in the global colorectal cancer
  therapeutics market. Insightful review of the key
  industry drivers, restraints and challenges. Each
  trend is independently researched to provide
  qualitative analysis of its implications.

11
Report Description

• Reasons to buy
• Develop and design your in-licensing and
  out-licensing strategies through a review of
  pipeline products and technologies, and by
  identifying the companies with the most robust
  pipeline.
• Develop business strategies by understanding the
  trends shaping and driving the global colorectal
  cancer therapeutics market.
• Drive revenues by understanding the key trends,
  innovative products and technologies, market
  segments, and companies likely to impact the
  global colorectal cancer therapeutics market in
  the future.
• Formulate effective sales and marketing
  strategies by understanding the competitive
  landscape and by analysing the performance of
  various competitors.

12
Report Description

• Reasons to buy
• Identify emerging players with potentially strong
  product portfolios and create effective
  counter-strategies to gain a competitive
  advantage.
• Organize your sales and marketing efforts by
  identifying the market categories and segments
  that present maximum opportunities for
  consolidations, investments and strategic
  partnerships.

13
FOR MORE DETAILS
Visit us at
http//www.bigmarketresearch.com/pharmapoint-color
ectal-cancer-global-drug-forecast-and-analysis-to-
2023-market
Stay With Us
5933 NE Win Sivers Drive,205, Portland, OR
97220United States
TELEPHONE [phone]E-MAIL
help_at_bigmarketresearch.com